Actionable insights — Buying more LIB in the $0.60s

1. Before averaging down, ask what the sell-off knows — and name the fear out loud so you can date it

1. Start from the drawdown, not the price. Ask the narrow question "what changed at the company?" — a missed milestone, a broken permit, a cost blowout, a departure, a financing on bad terms — before asking whether the stock is cheap. If nothing changed, the fall is flow or sentiment, and the position you already own is the same position.
2. Force yourself to name the specific fear the sellers are acting on. A vague "risk-off" answer means you haven't found it; a nameable one ("further dilution — for capex, or the US uplisting") can be checked.
3. Date the fear. Was it already in your thesis when you bought? An already-expected risk being re-priced is a price move without an information move, and that is the setup for adding. A newly-discovered risk being priced is the opposite — that is the setup for reassessing.
4. Be honest about what the fear could still cost you even when it is "expected." A dilution risk you priced in is not a dilution risk you sized; when it lands, the terms — price, warrants, who buys — determine whether your per-share value survives. Expecting the raise is not the same as expecting that raise.
5. Carry the risk statement forward verbatim as you average down. If the caveats in your second buy note read softer than the first, the extra size — not new evidence — is what moved them.

• The first facility coming into production this year — the one dated, falsifiable milestone the whole add rests on; a slip past year-end is the thesis, not the tape, being wrong.
• The financing when it comes (capex and/or the US uplisting): its price and terms, since the "already expected" defence only holds if the raise lands on ordinary terms.
• The tell that the diagnosis was wrong: the "no clear reason" verdict followed by company news that supplies one — a delay, a cost revision, an insider exit — which means the market had information first.